Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135283 | 1.00 | GAA (0.42) | GAAFAAHTRPV1SOAT2SOAT1 | |
| SCHEMBL16135277 | 1.00 | GAA (0.42) | GAAFAAHTRPV1SOAT2SOAT1 | |
| SCHEMBL16135284 | 0.95 | TRPV1 (0.42) | FAAHTRPV1SOAT1EPHX2ALDH1A1 | |
| SCHEMBL16162777 | 0.92 | GAA (0.40) | GAAFAAHTRPV1SOAT2SOAT1 | |
| SCHEMBL23345472 | 0.92 | TRPV1 (0.46) | GAAFAAHTRPV1MGLLMAPT | |
| SCHEMBL10384639 | 0.85 | MAPT (0.40) | GAAMAPTRAB9AALDH1A1TSHR | |
| SCHEMBL16135393 | 0.83 | RAB9A (0.39) | GAAMAPTRAB9AALDH1A1TSHR | |
| SCHEMBL499774 | 0.80 | GAA (0.45) | GAAMAPTRAB9AALDH1A1TSHR | |
| SCHEMBL28334229 | 0.77 | TSHR (0.52) | GAAALDH1A1TSHR | |
| SCHEMBL30487869 | 0.75 | GPR84 (0.50) | FAAHSOAT2SOAT1MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833129-B2 | Thiophene compound for treatment of exfoliating glaucoma | AVOSCIENCE, LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210137876-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | AVOSCIENCE, LLC (US) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137876-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | FAH, PHOSPHO1, FAP | GAA 1793/4885FAAH 51/4885TRPV1 1190/4885 |
| US-11833129-B2 | Thiophene compound for treatment of exfoliating glaucoma | TYMP, TDP1, TDP2 | GAA 580/4885FAAH 2334/4885TRPV1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.